Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13232183 | 0.78 | GAA (0.44) | PLA2G10PLA2G5GAAPOLBCYP1A2 | |
| SCHEMBL15712275 | 0.62 | LMNA (0.46) | GAAKMT2AALDH1A1 | |
| SCHEMBL9453746 | 0.61 | HDAC1 (0.60) | GAAPOLBKMT2AMMP2 | |
| SCHEMBL2156932 | 0.61 | CCR2 (0.53) | KMT2ACCR2ALDH1A1 | |
| SCHEMBL20499420 | 0.60 | MEN1 (0.55) | GAAKMT2AMMP2ALDH1A1 | |
| SCHEMBL9453685 | 0.60 | KMT2A (0.56) | PLA2G10PLA2G5GAAPOLBKMT2A | |
| SCHEMBL25290375 | 0.60 | RECQL (0.53) | KMT2ACCR2ALDH1A1 | |
| SCHEMBL2049090 | 0.60 | RECQL (0.53) | KMT2ACCR2ALDH1A1 | |
| SCHEMBL30491733 | 0.60 | RECQL (0.53) | KMT2ACCR2ALDH1A1 | |
| SCHEMBL18109234 | 0.60 | TDP1 (0.55) | GAAPOLBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100167933-A1 | Piperazine Compounds With Herbicidal Action | BASF SE (DE) | 2010-07-01 | — | — | US | disclosed |
| US-20100167933-A1 | Piperazine Compounds With Herbicidal Action | BASF SE (DE) | 2010-07-01 | — | — | US | disclosed |
| WO-2009000757-A1 | PIPERAZINE COMPOUNDS WITH HERBICIDAL ACTION | BASF SE (DE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100167933-A1 | Piperazine Compounds With Herbicidal Action | PRXL2A, CBR1, CBR3 | PLA2G10 3153/4885PLA2G5 1278/4885GAA 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.